USFDA Clears Alembic’s Difluprednate Emulsion, Boosting Ophthalmic Market Presence

Alembic Pharmaceuticals Ltd has received final approval from the US Food and Drug Administration (USFDA) for its Difluprednate Ophthalmic Emulsion, 0.05%, used in treating inflammation and pain associated with ocular surgery. The approval strengthens Alembic’s U.S. portfolio, enhancing its presence in ophthalmic therapies and expanding opportunities in the regulated generics market.

Show more

Stay Ahead – Explore Now! Tradition Meets Transition: Why Saraswati Puja Defines Growing Up In Bengal